SciClone Pharmaceuticals, Inc. (SCLN): Insiders Aren’t Crazy About It

Page 1 of 2

Is SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) an attractive investment today? The best stock pickers are becoming more confident. The number of long hedge fund bets moved up by 2 lately.

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

According to most traders, hedge funds are perceived as underperforming, outdated financial tools of yesteryear. While there are more than 8000 funds in operation at the moment, we at Insider Monkey look at the bigwigs of this club, around 450 funds. It is widely believed that this group oversees most of the hedge fund industry’s total capital, and by keeping an eye on their best equity investments, we have figured out a few investment strategies that have historically outstripped Mr. Market. Our small-cap hedge fund strategy outpaced the S&P 500 index by 18 percentage points per year for a decade in our back tests, and since we’ve started sharing our picks with our subscribers at the end of August 2012, we have topped the S&P 500 index by 24 percentage points in 7 months (see all of our picks from August).

Equally as beneficial, positive insider trading activity is a second way to break down the marketplace. As the old adage goes: there are lots of incentives for a corporate insider to downsize shares of his or her company, but just one, very simple reason why they would buy. Several empirical studies have demonstrated the valuable potential of this strategy if investors understand where to look (learn more here).

Now, it’s important to take a peek at the latest action surrounding SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

How have hedgies been trading SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)?

Heading into 2013, a total of 12 of the hedge funds we track were bullish in this stock, a change of 20% from the previous quarter. With hedge funds’ capital changing hands, there exists a select group of notable hedge fund managers who were boosting their stakes considerably.

Of the funds we track, AQR Capital Management, managed by Cliff Asness, holds the biggest position in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). AQR Capital Management has a $2.3 million position in the stock, comprising less than 0.1%% of its 13F portfolio. The second largest stake is held by Millennium Management, managed by Israel Englander, which held a $2.2 million position; less than 0.1%% of its 13F portfolio is allocated to the company. Other peers that hold long positions include Peter Algert and Kevin Coldiron’s Algert Coldiron Investors, Wilmot B. Harkey and Daniel Mack’s Nantahala Capital Management and John Overdeck and David Siegel’s Two Sigma Advisors.

As one would reasonably expect, key money managers have jumped into SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) headfirst. Nantahala Capital Management, managed by Wilmot B. Harkey and Daniel Mack, assembled the largest position in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Nantahala Capital Management had 0.9 million invested in the company at the end of the quarter. Neil Chriss’s Hutchin Hill Capital also made a $0.3 million investment in the stock during the quarter. The following funds were also among the new SCLN investors: Jim Simons’s Renaissance Technologies and Glenn Russell Dubin’s Highbridge Capital Management.

Insider trading activity in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

Insider purchases made by high-level executives is best served when the company in focus has experienced transactions within the past six months. Over the latest six-month time period, SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has seen zero unique insiders buying, and zero insider sales (see the details of insider trades here).

Let’s go over hedge fund and insider activity in other stocks similar to SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). These stocks are Pernix Therapeutics Holdings Inc (NASDAQ:PTX), Depomed Inc (NASDAQ:DEPO), DUSA Pharmaceuticals Inc (NASDAQ:DUSA), Lannett Company, Inc. (NYSEAMEX:LCI), and Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). All of these stocks are in the drug manufacturers – other industry and their market caps are closest to SCLN’s market cap.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!